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13; revised manuscript received September 4,complications after stent implantation remains high (1). To
minimize this risk, dual antiplatelet therapy (DAPT) is
mandatory and is recommended for several months (from
1 to 12 months, according to type of stent and clinical
presentation) (2,3). In the PRODIGY (Prolonging Dual
Antiplatelet Treatment After Grading Stent-Induced
Intimal Hyperplasia) trial, we found that a regimen of
24 months of DAPT was not signiﬁcantly more effective
than a 6-month regimen in reducing the composite of death,
myocardial infarction (MI), or cerebrovascular accident
(CVA) (4). On the contrary, a signiﬁcant increase in
bleeding complications was observed (4). Patients receiving
a further PCI procedure for in-stent restenosis (ISR) are
a subgroup of patients at very high risk of ischemic
complication and ST. It is still unclear if they have beneﬁt
from a prolonged DAPT regimen. In this substudy of the
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507PRODIGY trial (4,5), we sought to investigate the clinical
outcome of ISR patients randomized to short (6 months)
versus long (24 months) DAPT regimen.CVA = cerebrovascular
accident
DAPT = dual antiplatelet
therapy
DES = drug-eluting stent(s)
ISR = in-stent restenosis
MI = myocardial infarction
PCI = percutaneous coronary
intervention
ST = stent thrombosisMethods
Patients. This is a pre-speciﬁed substudy of the
PRODIGY trial (4,5). Accordingly, inclusion and exclusion
criteria have been previously reported (4–6). Brieﬂy, in the
PRODIGY’s main study, 1,970 patients undergoing PCI
with stent implantation were eligible and were randomized
to short (6 months) versus long (24 months) DAPT
regimen (Fig. 1) (4,6). As reported in Figure 1, there were
224 (11%) patients in the PRODIGY’s main study who had
angiographic evidence of ISR and were treated for it with
PCI and drug-eluting stent (DES) implantation. This is the
study population of the current analysis, which is consti-
tuted by 2 different groups (Fig. 1). Ninety-six patients were
stented at the time of the inclusion in the PRODIGY study
for ISR and represented the ﬁrst group of our study pop-
ulation (group A in Fig. 1). On the contrary, 128 patients
who had angiographic evidence of ISR during the
PRODIGY study, received a new PCI procedure for it.
They formed the second group of our study population
(group B in Fig. 1). They are included in this substudy at
the time of the PCI procedure for ISR. All adverse events
occurring from the PRODIGY enrollment to the new PCI
procedure for ISR were censored. Their follow-up restarts
from the time of the new PCI for ISR and they are
followed-up for another 24 months. In the remaining 1,746
patients, we did not observe any angiographic evidence of
ISR. The Ethics Committees of the participating centersFigure 1 Study Proﬁle
Description of the overall study population, of the groups studied in the current analysis a
therapy; ISR ¼ in-stent restenosis; MI ¼ myocardial infarction; pts ¼ patients.independently approved the pro-
tocol and all participants gave
written informed consent.
Treatment protocol. All pa-
tients received aspirin (80 to 160
mg orally) indeﬁnitely. On the
contrary, clopidogrel (75 mg
orally) is administered for a vari-
able duration according to the
randomization scheme. Patients
randomized to the short DAPT
regimen received it for 6 months,
whereas patients randomized to
the long DAPT regimen received it for 24 months (4,5). As
pre-speciﬁed (5), in the case of a new PCI procedure
needing stent implantation, the study protocol mandated the
use of the original randomization scheme. The patients in
group A were enrolled and randomized during the PCI
procedure for ISR, so they assumed aspirin plus clopidogrel
for 6 or 24 months after the PCI procedure according to
randomization allocation. On the contrary, the patients in
group B were previously enrolled in the PRODIGY trial and
developed ISR needing a new PCI procedure with DES
implantation during follow-up. For the patients in group B,
the time of the inclusion in the present sub-analysis is the
new PCI procedure for ISR. All previous adverse events
were censored. The follow-up started from the new PCI
procedure for ISR. As pre-speciﬁed (5), these patients
maintained the original randomization scheme. The patients
in group B previously allocated to the long DAPT regimen,
at the time of the PCI procedure for ISR, were still in aspirin
plus clopidogrel and they continued it for 24 months. Onnd of their randomization. CVA ¼ cerebrovascular accident; DAPT ¼ dual antiplatelet
Table 1 Baseline Characteristics of Patients
Patients With ISR
(n ¼ 224)
p1
Patients Without ISR
(n ¼ 1,746)
p2 p3 p4
Short DAPT
(n ¼ 114)
Long DAPT
(n ¼ 110)
Short DAPT
(n ¼ 869)
Long DAPT
(n ¼ 877)
Age (yrs) 70  10 68  10 0.3 68  11 68  10 0.8 0.3 0.8
Male 85 (75) 86 (78) 0.5 662 (76) 678 (77) 0.7 0.7 0.8
BMI (kg/m2) 29  3 28  3 0.5 29  3 28  3 0.8 0.9 0.9
Diabetes 35 (30) 36 (33) 0.5 198 (23) 208 (24) 0.7 0.2 0.2
Insulin 11 (10) 9 (8) 0.2 44 (5) 50 (6) 0.5 0.1 0.4
Hypertension 81 (71) 80 (72) 0.7 612 (70) 613 (70) 0.9 0.9 0.8
Dyslipidemia 71 (62) 73 (66) 0.3 454 (52) 480 (55) 0.4 0.3 0.2
Smokers 13 (12) 17 (15) 0.4 191 (21) 205 (23) 0.2 0.08 0.2
CrCl (ml/min) 69 [52–90] 73 [54–95] 0.2 76 [57–95] 74 [56–99] 0.3 0.4 0.6
Prior MI 50 (45) 48 (44) 0.5 226 (26) 222 (25) 0.6 <0.01 <0.01
Prior PCI 114 (100) 110 (100) 0.9 157 (18) 175 (20) 0.6 <0.01 <0.01
Prior CABG 18 (15) 13 (12) 0.3 87 (10) 97 (11) 0.8 0.1 0.9
Prior CVA 4 (4) 3 (2) 0.7 35 (4) 34 (3) 0.8 0.8 0.8
LVEF (%) 50  11 52  10 0.2 53  11 53  10 0.9 0.3 0.7
Clinical presentation
Stable angina 47 (43) 53 (48) 0.6 226 (26) 237 (27) 0.8 <0.01 <0.01
UA 35 (30) 32 (29) 0.8 165 (19) 158 (18) 0.7 0.03 0.04
NSTEMI 26 (22) 20 (19) 0.5 200 (23) 202 (23) 0.9 0.6 0.4
STEMI 6 (5) 5 (4) 0.8 278 (32) 280 (32) 0.9 <0.01 <0.01
Medical therapy at discharge
ACE-I 84 (73) 86 (78) 0.2 624 (72) 621 (71) 0.9 0.8 0.5
AII RB 11 (10) 10 (9) 0.9 108 (12) 109 (12) 0.9 0.7 0.4
Beta-blockers 90 (79) 90 (82) 0.8 659 (76) 660 (75) 0.8 0.6 0.4
Statins 97 (85) 96 (87) 0.7 714 (82) 722 (82) 0.8 0.7 0.5
PPI 42 (37) 40 (36) 0.9 260 (30) 304 (35) 0.4 0.3 0.9
Values are mean  SD, n (%), or median [interquartile range]. p1 is for the comparison short versus long in patients with ISR. p2 is for the comparison short versus long in patients without ISR. p3 is for the
comparison ISR versus no ISR in patients randomized to short DAPT. p4 is for the comparison ISR versus no ISR in patients randomized to long DAPT.
ACE-I ¼ angiotensin converting enzyme inhibitor; AII RB ¼ angiotensin II receptor blocker; BMI ¼ body mass index; CABG ¼ coronary artery bypass graft; CrCl ¼ creatinine clearance; CVA ¼ cerebrovascular
accident; DAPT ¼ dual antiplatelet therapy; LVEF ¼ left ventricular ejection fraction; MI ¼ myocardial infarction; NSTEMI ¼ no ST-segment elevation myocardial infarction; PCI ¼ percutaneous coronary
intervention; PPI ¼ proton pump inhibitor; STEMI ¼ ST-segment elevation myocardial infarction; UA ¼ unstable angina.
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508the contrary, the patients in group B previously allocated to
the short DAPT regimen were treated with aspirin plus
clopidogrel for an additional 6 months after the PCI
procedure for ISR. Afterward, they stopped clopidogrel and
continued only aspirin until the 2-year follow-up.
Follow-up. All randomized patients who were not lost
to follow-up, returned for study visits 30 days after hospi-
talization and the PCI procedure, and then every 6 months
for 2 years. During follow-up visits, patients were examined
and assessed for adverse events, and 12-lead electrocardio-
graphic recordings were obtained. At all follow-up time
points, patients were questioned regarding their compliance
with the study medication. Any interruptions or termination,
as well as the reasons for this, were documented.
Clinical endpoints. The primary objective of the present
study was the cumulative incidence of death of any cause,
nonfatal MI, or CVA at 24 months. Secondary endpoints
included each component of the primary endpoint, the
incidence of ST deﬁned on the basis of the Academic
Research Consortium criteria (7), target lesion revasculari-
zation, and target vessel revascularization. Safety endpoints
were bleeding complications classiﬁed according toThrombolysis In Myocardial Infarction (TIMI), Bleed
Score, and Bleeding Academic Research Consortium criteria
(8–10). The diagnosis of acute myocardial infarction was
based on the universal deﬁnition of myocardial infarction
(11). Stroke, as detected by the occurrence of a new
neurological deﬁcit, was conﬁrmed by a neurologist and
imaging, whereas the occurrence of a transient ischemic
attack required hospitalization and clinical conﬁrmation by
a neurologist. All study endpoints and bleeding events were
conﬁrmed on the basis of documentation collected at each
hospital and were centrally adjudicated by the clinical events
committee, whose members were unaware of patients’
treatment-group assignments (4–6).
Statistical analysis. Continuous data were tested for normal
distribution with the Kolmogorov-Smirnov test. Normally
distributed variables were presented as mean  SD and were
compared by Student t test. Otherwise, data were presented as
median and interquartile range, and the Mann-Whitney U
test was used. Of note, creatinine clearance, reference vessel
diameter, minimal lumen diameter, and number of stent
were not normally distributed. Categorical variables were
summarized in terms of number and percentages and were
Table 2 Angiographic Characteristics of Patients
Patients With ISR
(n ¼ 224)
p1
Patients Without ISR
(n ¼ 1,746)
p2 p3 p4
Short DAPT
(n ¼ 114)
Long DAPT
(n ¼ 110)
Short DAPT
(n ¼ 869)
Long DAPT
(n ¼ 877)
After BMS ISR 66 (58) 69 (62) 0.7
After DES ISR 48 (42) 41 (38) 0.6
Multivessel PCI 0 (0) 0 (0) 0.9 226 (26) 237 (27) 0.3 <0.01 <0.01
Target vessel
LAD 50 (44) 51 (46) 0.8 460 (53) 456 (52) 0.9 0.3 0.6
CFX 29 (25) 31 (28) 0.6 278 (32) 280 (32) 0.9 0.4 0.6
RCA 30 (26) 25 (23) 0.5 321 (37) 307 (35) 0.4 0.2 0.1
LM 4 (3) 3 (3) 0.9 52 (6) 52 (6) 0.8 0.5 0.3
SVG 9 (1) 17 (2) 0.3
QCA pre-procedure
RVD before (mm) 2.5 [2.1–2.8] 2.6 [2.2–3.0] 0.2 2.6 [2.2–2.9] 2.7 [2.3–2.9] 0.7 0.8 0.4
MLD before (mm) 0.5 [0.2–0.8] 0.6 [0.3–0.9] 0.3 0.5 [0.2–0.8] 0.5 [0.2–0.8] 0.8 0.4 0.8
Diameter of stenosis (%) 77  18 78  15 0.6 77  16 78  116 0.6 0.8 0.7
Lesion length, mm 20  8 21  9 0.8 14  9 15  9 0.6
ISR pattern
Focal 45 (41) 50 (45) 0.4
Diffuse intrastent 35 (30) 28 (26) 0.3
Diffuse proliferative 23 (20) 23 (21) 0.8
Diffuse total occlusion 11 (9) 9 (8) 0.9
Number of stent 2 [1–3] 2 [1–3] 0.9 1 [1–2] 1 [1–2] 0.3 0.4 0.2
QCA post-procedure
RVD before (mm) 2.8 [2.4–3.2] 2.9 [2.5–3.2] 0.6 2.8 [2.5–3.1] 2.8 [2.5–3] 0.8 0.9 0.9
MLD before (mm) 2.5 [2.2–2.9] 2.6 [2.3–2.8] 0.5 2.5 [2.2–2.8] 2.5 [2.2–2.8] 0.9 0.8 0.8
Diameter of stenosis (%) 10  8 10  9 0.7 10  7 10  7 0.9 0.7 0.7
Values are n (%), median [interquartile range], or mean  SD. p1 is for the comparison short versus long in patients with ISR. p2 is for the comparison short versus long in patients without ISR. p3 is for the
comparison ISR versus no ISR in patients randomized to short DAPT. p4 is for the comparison ISR versus no ISR in patients randomized to long DAPT.
BMS ¼ bare metal stent(s); CFX ¼ circumﬂex artery; DES ¼ drug-eluting stent(s); ISR ¼ in-stent restenosis; LAD ¼ left anterior descending; LM ¼ left main; MLD ¼ minimal lumen diameter; QCA ¼
quantitative coronary analysis; RCA ¼ right coronary artery; RVD ¼ reference vessel diameter; SVG ¼ saphenous vein graft; other abbreviations as in Table 1.
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509compared by using 2-sidedFisher’s exact test. Estimation of the
cumulative primary endpoint rate was performed by the
Kaplan-Meier method, and events were compared by the log-
rank test. Hazard ratios with 95% conﬁdence intervals were
calculated for the long DAPT regimen versus the short DAPT
regimen (e.g., values>1 indicated increased hazard in the long
DAPT regimen) with a proportional hazards model. To better
evaluate and describe the relationship between clopidogrel dis-
continuation (in the short DAPT regimen) and adverse events,
we performed analyses with the landmark set at 6 months.
We performed a Cox regression analysis with interaction
testing to determine whether the effect of duration of DAPT
on the primary endpoint was consistent across patients with
ISR versus those without ISR. The interaction test was
performed with likelihood ratio tests of the null hypothesis
that the interaction coefﬁcient was zero. A 2-sided value of
p < 0.05 was considered signiﬁcant. All analyses were per-
formed with STATISTICA version 8 (Statsoft Inc., Tulsa,
Oklahoma).
Results
Our study population included 224 patients undergoing new
PCI procedures for ISR. Overall, 114 patients were allocatedto the short DAPT regimen, whereas 110 patients were
allocated to the long DAPT regimen (Fig. 1). These 2
groups were balanced for the principal clinical and angio-
graphic characteristics (Tables 1 and 2). We did not observe
any difference in cardiovascular risk factors, medical history,
clinical presentation, and angiographic features between ISR
patients receiving short DAPT and those receiving long
DAPT. The adherence to the assigned DAPT regimen is
high (>95% in the long DAPT regimen and >97% in
the short DAPT regimen). At 6 months, the use of aspirin
plus clopidogrel was 95% in the short DAPT regimen
versus 98% in the long DAPT regimen (p ¼ 0.7). A 1 year,
it was 15% versus 97% (p < 0.01), whereas after 18 months
it was 2% versus 96% (p < 0.01), respectively. Of note, no
signiﬁcant differences were observed between patients in
group A versus B (Online Tables 1 and 2). The time
between enrollment in the PRODIGY study and the
second PCI procedure for ISR of the patients in group B
was 6.5  3 months (median 6.2 months; range 1 to 13
months; interquartile range 4 to 9 months). No differences
were present in the adherence to DAPT regimen comparing
group A and group B (p ¼ 0.7).
As expected and reported in Tables 1 and 2, patients with
ISR showed a higher occurrence of prior MI, prior PCI, and
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510stable angina at clinical presentation, as compared to those
without ISR.
Primary endpoint. In the group of patients treated for ISR,
16 (7%) patients died, a total of 12 (5%) had an MI, and 3
(1%) had a CVA (Table 3). Overall, 27 (12%) patients
reached the primary endpoint (19 in the short DAPT
regimen vs. 8 in the long DAPT regimen; p ¼ 0.02). The
Kaplan-Meier estimate of the event rate for the primary
endpoint was 16.7% in the short DAPT regimen group
compared with 7.3% in the long DAPT regimen group (p ¼
0.034) (Fig. 2). Four adverse events occurred in the ﬁrst 6
months after the PCI procedure for ISR. These 4 adverse
events occurred during aspirin plus clopidogrel treatment (3
in the short DAPT regimen vs. 1 in the long DAPT
regimen; p ¼ 0.2) (Online Fig. 1). The remaining 23
adverse events occurred after the sixth month. Seven were
observed in the long DAPT regimen during aspirin
plus clopidogrel treatment, whereas 16 occurred in the
short DAPT regimen after clopidogrel discontinuation
(p ¼ 0.065) (Online Fig. 1).
Considering the patients without angiographic evidence
of ISR, 156 (8.7%) patients reached the primary endpoint
(78 in the short DAPT regimen vs. 78 in the long DAPT
regimen; p ¼ 0.9). The Kaplan-Meier estimate of the event
rate for the primary endpoint was 8.8% in the short DAPTTable 3 Efﬁcacy and Safety Secondary Clinical Endpoints
Short DAPT
(n ¼ 114)
Long DAPT
(n ¼ 110) p Value
Ischemic secondary endpoints
Death 12 (10.5) 4 (3.5) 0.04
MI 9 (8) 3 (3) 0.07
Death and MI 18 (16) 7 (6) 0.03
CVA 1 (1) 2 (2) 0.4
Deﬁnite and probable
stent thrombosis
3 (2.5) 0 (0) 0.1
Deﬁnite, probable, possible
stent thrombosis
7 (6) 3 (2.5) 0.3
TLR 17 (15) 15 (14) 0.8
TVR 17 (15) 19 (17) 0.4
Bleeding safety endpoints
TIMI
Major 0 (0) 1 (1) 0.5
Minor 2 (2) 1 (1) 0.7
BARC
2 5 (4) 2 (2) 0.2
3 2 (2) 2 (2) 0.6
5 0 (0) 1 (1) 0.7
Bleed score
0 91 (80) 86 (78) 0.8
1 1 (1) 2 (2) 0.6
2 3 (2) 4 (4) 0.5
3 10 (9) 9 (8) 0.8
4 1 (1) 2 (2) 0.9
5 8 (7) 7 (6) 0.7
Values are n (%). CVA also represents stroke and transient ischemic attack in this table.
BARC ¼ bleeding academic research consortium; TIMI ¼ Thrombolysis In Myocardial Infarction;
TLR ¼ target lesion revascularization; TVR ¼ target vessel revascularization; other abbreviations as
in Table 1.regimen group compared with 8.7% in the long DAPT
regimen group (p ¼ 0.85). The interaction test, including
DAPT regimen and presence or not of ISR, reached statis-
tical signiﬁcance (Fig. 3). Finally, there was no difference
between group A and B (Online Table 3, Online Fig. 2).
Secondary ischemic endpoints in patients with ISR. As
shown in Table 3, we observed a lower occurrence of death
in the long DAPT regimen group as compared with the
short DAPT regimen group (3.5% vs. 10.5%; p ¼ 0.04).
There was also a trend to have less MI in the long DAPT
regimen (3% vs. 8%; p ¼ 0.07). The cumulative incidence of
death and MI is 15.5% in the short DAPT regimen versus
6.3% in the long DAPT regimen (p ¼ 0.03). Three of these
adverse events occurred in the ﬁrst 6 months (2 in the short
DAPT regimen vs. 1 in the long DAPT regimen; p ¼ 0.6)
(Fig. 4). The remaining 22 occurred after the sixth month
(6 in the long DAPT regimen during aspirin plus clopi-
dogrel treatment vs. 16 in the short DAPT regimen after
clopidogrel discontinuation; p ¼ 0.025) (Fig. 4). No di-
fferences were observed in the other secondary endpoints
(Table 3). Groups A and B showed a similar occurrence of
secondary ischemic endpoints (Online Table 3).
Bleeding complications in patients with ISR. Among the
patients assigned to receive the long DAPT regimen
compared with those assigned to receive the short DAPT
regimen, there was no difference in the occurrence of
bleeding complications (Table 3). We did not observe
signiﬁcant differences between groups A and B (Table 3).
Discussion
To the best of our knowledge, this is the ﬁrst analysis
describing the efﬁcacy and safety of a prolonged DAPT
regimen in patients treated for ISR. In our study population
(n ¼ 224), we found that the long DAPT regimen is
associated with a signiﬁcant reduction of death, MI, andFigure 2 Cumulative Incidence of Primary Endpoint
Abbreviations as in Figure 1.
Figure 3 Subgroup Analysis of the Primary Endpoint
Subgroup analysis is shown with hazard ratios and 95% conﬁdence intervals (CIs)
for the primary endpoint among subgroups of patients (with ISR vs. without ISR)
randomly assigned to long versus short DAPT regimen. The probability value for
interaction represents the likelihood of interaction between the variable and the
relative treatment effect. Abbreviations as in Figure 1.
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511CVA as compared with the short DAPT regimen. Partic-
ularly, we observed a signiﬁcant reduction of death and-
MI in patients with ISR randomized to the long
DAPT regimen. This beneﬁt was not present in the
group of patients without angiographic evidence of ISR.
Interestingly, patients with ISR randomized to the long
DAPT regimen did not show an increase in the risk of
bleeding complication, independently to the classiﬁcation
used.
As previously reported (4–6), the principal strengths of
the PRODIGY trial were the minimally selected study
population reﬂecting the daily clinical practice, the prospec-
tive collection of adverse events and their blindedFigure 4
Cumulative Incidence of Death and MI
(Landmark Analysis)
Landmark analysis at 6 months (time of clopidogrel discontinuation in the short
DAPT regimen group). Abbreviations as in Figure 1.adjudication. In this sub-analysis of the PRODIGY trial we
focused our attention on patients with ISR. This is
a subgroup of patients poorly evaluated in previous stud-
ies, but with a high recurrence of ischemic complica-
tions including death, ST, reinfarction, and target vessel
revascularization (12,13). In this sub-analysis, we collected an
extended follow-up of 2 years and, for the ﬁrst time, we
studied the efﬁcacy of 2 different regimens for inhibition of
platelet aggregation (6 months vs. 2 years) in this particular
subset of patients.
In the PRODIGY study, we showed that an extended
use of DAPT (24 months) was not signiﬁcantly more
effective than a 6-month duration followed by aspirin
monotherapy in reducing the risk of major adverse cardiac
and cerebrovascular events (4). Conversely, long-term
duration of dual antiplatelet therapy was associated with
higher bleeding events and blood transfusion (5). This is
consistent with what some authors have described (14,15),
whereas other authors have reported conﬂicting results
(16,17). In this sub-analysis we identiﬁed a subgroup of
patients in which the administration of a prolonged DAPT
regimen is associated with a signiﬁcant reduction of death
and MI. This protective effect is maintained over time
and it is not related to an increase in the rate of bleeding
complications.
In the PRODIGY’s main study, the lack of beneﬁt
of the long DAPT regimen was consistent across several
subgroups (e.g., female sex, multiple lesions treatment,
complex lesions, reduced creatinine clearance). A tendency
toward more composite ischemic events in the long DAPT
regimen group was noted in some low-risk patients (e.g.,
younger patients or individuals who presented with stable
coronary artery disease) (4). Previous studies showed a rela-
tionship between study population risk proﬁle and efﬁcacy/
beneﬁt of the DAPT. In the CHARISMA (Clopidogrel for
High Atherothrombotic Risk and Ischemic Stabilization,
Management, and Avoidance) trial, clopidogrel addition to
aspirin was beneﬁcial in patients with documented history of
vascular disease, whereas it was harmful in those with only
multiple risk factors (very low-risk population) (18). Subjects
with diabetes mellitus and/or ST-segment elevation MI,
normally considered to be very high risk subgroups, showed
a greater net clinical beneﬁt (less ischemic adverse events
with no increase in bleeding complications) if treated with
a more intensive oral antiplatelet therapy (prasugrel vs. clo-
pidogrel) (19,20). According to this hypothesis and data, we
may speculate that those undergoing PCI for ISR are
patients at very high risk for ischemic complications and
therefore may beneﬁt from a more aggressive antiplatelet
regimen. Indeed, a prolonged DAPT regimen is clearly
associated with a reduction of ischemic endpoints in patients
receiving a new PCI procedure with DES for ISR.
Study limitations. This is a complementary study of the
PRODIGY trial, so several limitations are present. First,
there is no formal sample size calculation and thus our data
should be regarded as hypothesis-generating. Second, we
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512included 2 different groups of patients (group A and group B)
(Fig. 1). Nevertheless, as clearly reported in the Online
Tables 1 and 2, these 2 groups are similar regarding baseline
and angiographic characteristics, and also with outcome
measurements. Finally, clopidogrel is the only P2Y12 antag-
onist received by our patients. It is unknown if the adminis-
tration of ticagrelor or prasugrel will be associated with the
same or better result; therefore, future studies are clearly on
demand. Finally, all our patients received DES implantation
during the procedure for ISR. Thus, our data are not appli-
cable for patients treated with only conventional balloon
angioplasty or with a drug-eluting balloon.
Conclusions
Our study offers preliminary evidence that patients receiving
a new PCI procedure for ISR may beneﬁt from a long-term
administration of aspirin plus clopidogrel.
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